FDA Warns Against Hepatitis B Reactivation In Some Patients Taking Direct-Acting Hepatitis C Antivirals

The FDA warned against the potential risk of Hepatitis B virus reactivation in patients treated with direct-acting antiviral drugs for Hepatitis C. 'Boxed Warnings' about Hepatitis B reactivation risks on antiviral drug labels are now mandated.